Testimonial 2

“Guerbet has recently partnered with RadMD for several European, US and Canadian NDA submissions including Lipiodol (diagnostic indication) Lipiodol (therapeutic indication), Dotarem (CNS indication). RadMD has played a critical role in these submissions and approvals. Dr. Kohkan Shamsi led the RadMD team that provided ISS and ISE as well statistical expertise and medical writing  in preparation of these NDA submission. A key contributing factor to this successful collaboration is Dr.Shamsi’s vast experience in contrast agent clinical development and related regulatory issues which has certainly contributed to the success of these projects.”

Read More
Testimonial 3

“Dr. Patt and colleagues at RadMD leave no stone unturned when interrogating imaging data.  Dr. Patt has developed a novel methodology to take the typical RECIST 1.1 analysis and an ordinary CT scan from a clinical trial, and do a deep-dive exploration of the data to maximize the value of an image.  As clinical trials become more focused on the type of therapy, genomics and even the microbiome and less on the origin of the tumor, it will be essential that no data is left behind – every bit of information may be critical. While RadMD is also quite well known for their impressive radiologist training curriculum and radiologists readers, they are carving a new niche for themselves in the clinical trial world.”

Read More